EpilepsyNCT02497105
Ketogenic Diet Program for Epilepsy
A study testing Ketogenic Diet in people with Epilepsy, run by Shriners Hospitals for Children at 1 site in United States.
Trial summary
This study will assess the effectiveness of the ketogenic diet (high-fat, low-carbohydrate, and moderate protein) in treating epilepsy. Two study groups will be comprised of children with epilepsy (0-18 years of age) and whether or not they receive the ketogenic diet - epilepsy/ketogenic diet and… Read more about this study
- Who is it for?
- Ages 6 months to 18 yearsHealthy volunteers can take part
- Conditions the study is for
- Epilepsy
- What is being tested?
- Ketogenic Diet
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteUnited States
- Study dates
- Jan 2015to 19 Jan 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 months to 18 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Who may be able to join
- Ages 0-18 years.
- Primary diagnosis of epilepsy.
- Parent/legal guardian and child able to read or understand English, and able/willing to provide informed consent/assent.
- Females of childbearing potential must have a negative pregnancy test result and agree to use a medically acceptable method of contraception throughout the entire study period and for 30 days after the last dose of study drug - childbearing potential is defined a girls who are > Tanner stage 2 and urine pregnancy tests are acceptable.
Who cannot join
- Known cardiac disorder including arrhythmias or hypertension.
- Carnitine deficiency (primary).
- Carnitine palmitoyltransferase (CPT) I or II deficiency.
- Carnitine translocase deficiency.
- Beta-oxidation defects - medium-chain acyl dehydrogenase deficiency (MCAD), long-chain acyl dehydrogenase deficiency (LCAD), short-chain acyld dehydrogenase deficiency (SCAD), long-chain 3-hydroxyacyl-coenzyme A (CoA) deficiency, and medium-chain 3-hydroxyacyl-CoA deficiency.
- Pyruvate carboxylase deficiency.
Show all 9Show fewer
- Porphyria.
- Inability to maintain adequate nutrition.
- Patient or caregiver non-compliance.
Trial locations and contacts
1 site in 1 country.
United States1 site
Shriners Hospitals for Children - Honolulu
Honolulu, Hawaii, 96826-1099
About this study
This study will assess the effectiveness of the ketogenic diet (high-fat, low-carbohydrate, and moderate protein) in treating epilepsy. Two study groups will be comprised of children with epilepsy (0-18 years of age) and whether or not they receive the ketogenic diet - epilepsy/ketogenic diet and epilepsy/non-ketogenic diet.
Read the detailed description
According to an evidence-based guideline on the diagnosis and management of epilepsy from the National Institute for Clinical Excellence (2012), the ketogenic diet may be considered as an adjunctive treatment in children with drug-resistant epilepsy. Vast anecdotal and Class 1 studies have confirmed that the ketogenic diet helps most children with intractable seizures and cures many. Dietary therapies for epilepsy (e.g., classic ketogenic diet) have been shown to be highly effective. For example, Lee (P.R.) and Kossoff reported that approximately 50% of children with drug-resistant epilepsy had a greater than 50% reduction in seizures within days to months of treatment. In addition, use of the ketogenic diet as a treatment for epilepsy has been shown to reduce the escalating costs associated managing poorly controlled seizures (e.g., decrease in outpatient and emergency visits, inpatient hospitalization, neuroimaging, electro-encephalography, lab testing, and medication use).
If a child's seizures continue after two to three seizure medications have been tried, the ketogenic diet should be considered. However, many parents still medicate their children well beyond these guidelines and tolerate seizure frequency because they have no other alternatives. Given the physical and emotional toll that recurring seizures exact upon these children/families, the potential for improvement with the ketogenic diet is substantial. However, the ketogenic diet remains unavailable to most children.
Approximately 1% of Hawaii's children are projected to have epilepsy, but there is no established, ketogenic diet program for them to receive this dietary intervention, which can incorporate culturally distinct foods to improve palatability and compliance. Although the ketogenic diet has shown promise for broadening the scope of therapeutic options for children with epilepsy, it requires further study in an ethnically diverse population. At Shriners Hospitals for Children-Honolulu, the investigators have initiated a ketogenic and related dietary (e.g., modified Atkins diet) intervention program for children with epilepsy and started to assess its efficacy in treating epilepsy/seizures. This program also includes educational seminars and services to patients residing on the other Hawaii islands through outreach trips. The investigators have begun to enroll children with epilepsy into two groups based on whether or not they receive the ketogenic diet - epilepsy/ketogenic diet and epilepsy/non-ketogenic diet; total estimate of 15-30 participants over three years. Based upon initial findings, the investigators will implement a comprehensive, multidisciplinary ketogenic diet program that will potentially reach hundreds of children throughout Hawaii, the Pacific Basin, and elsewhere.
Specific Aims:
Aim 1. To assess the therapeutic efficacy of the ketogenic diet on epilepsy/seizures.
Hypothesis: Participants who have epilepsy/on the ketogenic diet will have significantly decreased number and severity of seizures than those that are not on the ketogenic diet, between baseline to three and six months after the dietary intervention is initiated.
Aim 2. In anticipation of lessened epilepsy/seizures, to determine the (a) change in number and dose of seizure medications used, (b) change in number of lab tests ordered for epilepsy management, (c) change in number of emergency room and hospital visits for seizures (or other neurodevelopmental problems), (d) change in number of neurologic procedures for epilepsy management (e.g. EEG, MRI, CT), and (e) participant/family satisfaction with the ketogenic diet.
Hypothesis: The number and/or dosage of medications, lab tests ordered, emergency room or hospital visits, and neurologic procedures for epilepsy management will decrease, and participant/family satisfaction will be high for participants who have epilepsy/on the ketogenic diet than those that are not on the ketogenic diet, between baseline to three and six months after the dietary intervention is initiated.
Aim 3. To compare differences and/or changes in (a) serum and urine ketone levels and (b) biochemical profiles as defined from blood and stool (gut or fecal microbiome) specimen samples.
Hypothesis: Participants who have epilepsy/on the ketogenic diet will have significantly higher serum/urine ketone levels and notably different biochemical profiles than those that are not on the ketogenic diet, between baseline to three and six months after the dietary intervention is initiated.
Children helped by the ketogenic diet are more likely to reach their highest level of functioning and become contributing adults. By providing the ketogenic diet as an intervention therapy for epilepsy in a safe and data-driven manner, the community-at-large will benefit and medical knowledge concerning dietary treatment for neurodevelopmental disorders will be advanced.
- Conditions
- Epilepsy
- Being tested
- Ketogenic Diet
- Keywords
- Epilepsy, Intractable Seizures, Ketogenic Diet, Biochemical Profiles
- Medical subject headings
- Epilepsy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ketogenic DietOther
Dietary
| Study group | Role | What they receive |
|---|---|---|
| Epilepsy/Ketogenic Diet | Experimental | Children (0-18 years of age) diagnosed with epilepsy will receive the ketogenic diet intervention. Receives: Other: Ketogenic Diet |
| Epilepsy/Non-Ketogenic Diet | No intervention | Children (0-18 years of age) diagnosed with epilepsy will not receive the ketogenic diet intervention. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline in the core symptoms of epilepsy (seizure frequency/severity)
Assess the number of epileptic seizures through review/analysis of responses to the seizure log (self-report)
Measured: Pre- and post-ketogenic diet intervention (at baseline, and after three and six months on the ketogenic diet)
Secondary outcomes (7)
Change from baseline in the number of medications used for epilepsy management
Assess changes through the review/analysis of self-report and medical record data
Measured: Pre- and post-ketogenic diet intervention (at baseline, and after three and six months on the ketogenic diet)
Change from baseline in the dosage of medications used for epilepsy management
Assess changes through the review/analysis of self-report and medical record data
Measured: Pre- and post-ketogenic diet intervention (at baseline, and after three and six months on the ketogenic diet)
Change from baseline in the number of lab tests ordered for epilepsy management
Assess changes through the review/analysis of self-report and medical record data
Measured: Pre- and post-ketogenic diet intervention (at baseline, and after three and six months on the ketogenic diet)
Change from baseline in the number of emergency room or hospital visits for epilepsy management
Assess changes through the review/analysis of self-report and medical record data
Measured: Pre- and post-ketogenic diet intervention (at baseline, and after three and six months on the ketogenic diet)
Change from baseline in subject/family satisfaction with the ketogenic diet
Assess changes through the review/analysis of self-report and medical record data
Measured: Pre- and post-ketogenic diet intervention (at baseline, and after three and six months on the ketogenic diet)
Change from baseline in ketone levels due to the ketogenic diet
Assess ketone level differences and changes through the analysis of serum and urine
Measured: Pre- and post-ketogenic diet intervention (at baseline, and after three and six months on the ketogenic diet)
Change from baseline in biochemical profiles due to the ketogenic diet
Assess biochemical profile differences and changes through the analysis of blood and stool (gut microbiome) specimen samples
Measured: Pre- and post-ketogenic diet intervention (at baseline, and after three and six months on the ketogenic diet)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jul 2015 (estimated)
- Study startJan 2015
- Primary completion19 Jan 2018
- Study completion19 Jan 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (19)Papers the sponsor has linked to this study.
- Other trials for EpilepsyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- Shriners Hospitals for Children
- Sponsor type
- University, hospital or other
- Collaborators
- University of Hawaii
- Responsible party
- Principal investigator, Ryan Lee, MD, Shriners Hospitals for Children
- Investigators
- Ryan W Lee, MD, Principal investigator, Shriners Hospitals for Children, Honolulu
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02497105
- Sponsor's protocol ID
- HON1402
- Status last verified
- Sep 2019
- First submitted
- 9 Jul 2015
- Last updated
- 20 Sep 2019
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- No
Publications
http://www.aetna.com/cpb/medical/data/200_299/0226.html Clinical Policy Bulletin: Hospitalization for the Initiation of Ketogenic Diet for the Treatment of Intractable Seizures. Accessed November 14, 2013.
Cervenka MC, Kossoff EH. Dietary treatment of intractable epilepsy. Continuum (Minneap Minn). 2013 Jun;19(3 Epilepsy):756-66. doi: 10.1212/01.CON.0000431396.23852.56.
PubMed 23739109National Clinical Guideline Centre (UK). The Epilepsies: The Diagnosis and Management of the Epilepsies in Adults and Children in Primary and Secondary Care: Pharmacological Update of Clinical Guideline 20. London: Royal College of Physicians (UK); 2012 Jan. Available from http://www.ncbi.nlm.nih.gov/books/NBK247130/
PubMed 25340221http://www.charliefoundation.org/offering-hope.html Accessed November 14, 2013
Lee PR, Kossoff EH. Dietary treatments for epilepsy: management guidelines for the general practitioner. Epilepsy Behav. 2011 Jun;21(2):115-21. doi: 10.1016/j.yebeh.2011.03.008. Epub 2011 Apr 21.
PubMed 21514240Williams E, Abrahams J, Maguire A, Harris G. A parent's perspective on dietary treatments for epilepsy. Epilepsy Res. 2012 Jul;100(3):338-43. doi: 10.1016/j.eplepsyres.2011.09.024. Epub 2012 May 8.
PubMed 22575229Kossoff EH, Caraballo RH, du Toit T, Kim HD, MacKay MT, Nathan JK, Philip SG. Dietary therapies: a worldwide phenomenon. Epilepsy Res. 2012 Jul;100(3):205-9. doi: 10.1016/j.eplepsyres.2011.05.024.
PubMed 21856128Gilbert DL, Pyzik PL, Vining EP, Freeman JM. Medication cost reduction in children on the ketogenic diet: data from a prospective study. J Child Neurol. 1999 Jul;14(7):469-71. doi: 10.1177/088307389901400712.
PubMed 10573471Mandel A, Ballew M, Pina-Garza JE, Stalmasek V, Clemens LH. Medical costs are reduced when children with intractable epilepsy are successfully treated with the ketogenic diet. J Am Diet Assoc. 2002 Mar;102(3):396-8. doi: 10.1016/s0002-8223(02)90091-x.
PubMed 11902372Vining EP, Freeman JM, Ballaban-Gil K, Camfield CS, Camfield PR, Holmes GL, Shinnar S, Shuman R, Trevathan E, Wheless JW. A multicenter study of the efficacy of the ketogenic diet. Arch Neurol. 1998 Nov;55(11):1433-7. doi: 10.1001/archneur.55.11.1433.
PubMed 9823827Freeman JM, Vining EP, Pillas DJ, Pyzik PL, Casey JC, Kelly LM. The efficacy of the ketogenic diet-1998: a prospective evaluation of intervention in 150 children. Pediatrics. 1998 Dec;102(6):1358-63. doi: 10.1542/peds.102.6.1358.
PubMed 9832569Neal EG, Chaffe H, Schwartz RH, Lawson MS, Edwards N, Fitzsimmons G, Whitney A, Cross JH. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol. 2008 Jun;7(6):500-6. doi: 10.1016/S1474-4422(08)70092-9. Epub 2008 May 2.
PubMed 18456557Henderson CB, Filloux FM, Alder SC, Lyon JL, Caplin DA. Efficacy of the ketogenic diet as a treatment option for epilepsy: meta-analysis. J Child Neurol. 2006 Mar;21(3):193-8. doi: 10.2310/7010.2006.00044.
PubMed 16901419Beghi E, Frigeni B, Beghi M, De Compadri P, Garattini L. A review of the costs of managing childhood epilepsy. Pharmacoeconomics. 2005;23(1):27-45. doi: 10.2165/00019053-200523010-00003.
PubMed 15693726de Kinderen RJ, Lambrechts DA, Postulart D, Kessels AG, Hendriksen JG, Aldenkamp AP, Evers SM, Majoie MH. Research into the (Cost-) effectiveness of the ketogenic diet among children and adolescents with intractable epilepsy: design of a randomized controlled trial. BMC Neurol. 2011 Jan 25;11:10. doi: 10.1186/1471-2377-11-10.
PubMed 21262002
Study at a glance
From the registry record, last updated by the sponsor on 20 Sep 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Ketogenic Diet Program for Epilepsy
- ClinicalTrials.gov ID
- NCT02497105
- Acronym / sponsor ID
- HON1402
- Conditions
- Epilepsy
- Keywords
- Epilepsy, Intractable Seizures, Ketogenic Diet, Biochemical Profiles
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- Shriners Hospitals for ChildrenUniversity, hospital or other
- Collaborators
- University of Hawaii
- Study start
- Jan 2015
- Primary completion
- 19 Jan 2018 (actual)
- Study completion
- 19 Jan 2018 (actual)
- First posted
- 14 Jul 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will assess the effectiveness of the ketogenic diet (high-fat, low-carbohydrate, and moderate protein) in treating epilepsy. Two study groups will be comprised of children with epilepsy (0-18 years of age) and whether or not they receive the ketogenic diet - epilepsy/ketogenic diet and epilepsy/non-ketogenic diet.
Detailed description
According to an evidence-based guideline on the diagnosis and management of epilepsy from the National Institute for Clinical Excellence (2012), the ketogenic diet may be considered as an adjunctive treatment in children with drug-resistant epilepsy. Vast anecdotal and Class 1 studies have confirmed that the ketogenic diet helps most children with intractable seizures and cures many. Dietary therapies for epilepsy (e.g., classic ketogenic diet) have been shown to be highly effective. For example, Lee (P.R.) and Kossoff reported that approximately 50% of children with drug-resistant epilepsy had a greater than 50% reduction in seizures within days to months of treatment. In addition, use of the ketogenic diet as a treatment for epilepsy has been shown to reduce the escalating costs associated managing poorly controlled seizures (e.g., decrease in outpatient and emergency visits, inpatient hospitalization, neuroimaging, electro-encephalography, lab testing, and medication use).
If a child's seizures continue after two to three seizure medications have been tried, the ketogenic diet should be considered. However, many parents still medicate their children well beyond these guidelines and tolerate seizure frequency because they have no other alternatives. Given the physical and emotional toll that recurring seizures exact upon these children/families, the potential for improvement with the ketogenic diet is substantial. However, the ketogenic diet remains unavailable to most children.
Approximately 1% of Hawaii's children are projected to have epilepsy, but there is no established, ketogenic diet program for them to receive this dietary intervention, which can incorporate culturally distinct foods to improve palatability and compliance. Although the ketogenic diet has shown promise for broadening the scope of therapeutic options for children with epilepsy, it requires further study in an ethnically diverse population. At Shriners Hospitals for Children-Honolulu, the investigators have initiated a ketogenic and related dietary (e.g., modified Atkins diet) intervention program for children with epilepsy and started to assess its efficacy in treating epilepsy/seizures. This program also includes educational seminars and services to patients residing on the other Hawaii islands through outreach trips. The investigators have begun to enroll children with epilepsy into two groups based on whether or not they receive the ketogenic diet - epilepsy/ketogenic diet and epilepsy/non-ketogenic diet; total estimate of 15-30 participants over three years. Based upon initial findings, the investigators will implement a comprehensive, multidisciplinary ketogenic diet program that will potentially reach hundreds of children throughout Hawaii, the Pacific Basin, and elsewhere.
Specific Aims:
Aim 1. To assess the therapeutic efficacy of the ketogenic diet on epilepsy/seizures.
Hypothesis: Participants who have epilepsy/on the ketogenic diet will have significantly decreased number and severity of seizures than those that are not on the ketogenic diet, between baseline to three and six months after the dietary intervention is initiated.
Aim 2. In anticipation of lessened epilepsy/seizures, to determine the (a) change in number and dose of seizure medications used, (b) change in number of lab tests ordered for epilepsy management, (c) change in number of emergency room and hospital visits for seizures (or other neurodevelopmental problems), (d) change in number of neurologic procedures for epilepsy management (e.g. EEG, MRI, CT), and (e) participant/family satisfaction with the ketogenic diet.
Hypothesis: The number and/or dosage of medications, lab tests ordered, emergency room or hospital visits, and neurologic procedures for epilepsy management will decrease, and participant/family satisfaction will be high for participants who have epilepsy/on the ketogenic diet than those that are not on the ketogenic diet, between baseline to three and six months after the dietary intervention is initiated.
Aim 3. To compare differences and/or changes in (a) serum and urine ketone levels and (b) biochemical profiles as defined from blood and stool (gut or fecal microbiome) specimen samples.
Hypothesis: Participants who have epilepsy/on the ketogenic diet will have significantly higher serum/urine ketone levels and notably different biochemical profiles than those that are not on the ketogenic diet, between baseline to three and six months after the dietary intervention is initiated.
Children helped by the ketogenic diet are more likely to reach their highest level of functioning and become contributing adults. By providing the ketogenic diet as an intervention therapy for epilepsy in a safe and data-driven manner, the community-at-large will benefit and medical knowledge concerning dietary treatment for neurodevelopmental disorders will be advanced.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Epilepsy/Ketogenic Diet | Experimental | Other: Ketogenic DietChildren (0-18 years of age) diagnosed with epilepsy will receive the ketogenic diet intervention. |
| Epilepsy/Non-Ketogenic Diet | No intervention | –Children (0-18 years of age) diagnosed with epilepsy will not receive the ketogenic diet intervention. |
Who may qualify
- Ages
- 6 months to 18 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
Key inclusion criteria (4 listed)
- Ages 0-18 years.
- Primary diagnosis of epilepsy.
- Parent/legal guardian and child able to read or understand English, and able/willing to provide informed consent/assent.
- Females of childbearing potential must have a negative pregnancy test result and agree to use a medically acceptable method of contraception throughout the entire study period and for 30 days after the last dose of study drug - childbearing potential is defined a girls who are > Tanner stage 2 and urine pregnancy tests are acceptable.
Key exclusion criteria (9 listed)
- Known cardiac disorder including arrhythmias or hypertension.
- Carnitine deficiency (primary).
- Carnitine palmitoyltransferase (CPT) I or II deficiency.
- Carnitine translocase deficiency.
- Beta-oxidation defects - medium-chain acyl dehydrogenase deficiency (MCAD), long-chain acyl dehydrogenase deficiency (LCAD), short-chain acyld dehydrogenase deficiency (SCAD), long-chain 3-hydroxyacyl-coenzyme A (CoA) deficiency, and medium-chain 3-hydroxyacyl-CoA deficiency.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ketogenic DietDietary | Other | Epilepsy/Ketogenic Diet |
Primary outcome
Change from baseline in the core symptoms of epilepsy (seizure frequency/severity)
Time frame: Pre- and post-ketogenic diet intervention (at baseline, and after three and six months on the ketogenic diet)
Assess the number of epileptic seizures through review/analysis of responses to the seizure log (self-report)
7 secondary outcomes
Change from baseline in the number of medications used for epilepsy management
Time frame: Pre- and post-ketogenic diet intervention (at baseline, and after three and six months on the ketogenic diet)
Change from baseline in the dosage of medications used for epilepsy management
Time frame: Pre- and post-ketogenic diet intervention (at baseline, and after three and six months on the ketogenic diet)
Change from baseline in the number of lab tests ordered for epilepsy management
Time frame: Pre- and post-ketogenic diet intervention (at baseline, and after three and six months on the ketogenic diet)
Change from baseline in the number of emergency room or hospital visits for epilepsy management
Time frame: Pre- and post-ketogenic diet intervention (at baseline, and after three and six months on the ketogenic diet)
Change from baseline in subject/family satisfaction with the ketogenic diet
Time frame: Pre- and post-ketogenic diet intervention (at baseline, and after three and six months on the ketogenic diet)
Change from baseline in ketone levels due to the ketogenic diet
Time frame: Pre- and post-ketogenic diet intervention (at baseline, and after three and six months on the ketogenic diet)
Change from baseline in biochemical profiles due to the ketogenic diet
Time frame: Pre- and post-ketogenic diet intervention (at baseline, and after three and six months on the ketogenic diet)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Sep 2019.
- Backgroundhttp://www.aetna.com/cpb/medical/data/200_299/0226.html Clinical Policy Bulletin: Hospitalization for the Initiation of Ketogenic Diet for the Treatment of Intractable Seizures. Accessed November 14, 2013.
- Background: PubMed 23739109Cervenka MC, Kossoff EH. Dietary treatment of intractable epilepsy. Continuum (Minneap Minn). 2013 Jun;19(3 Epilepsy):756-66. doi: 10.1212/01.CON.0000431396.23852.56.
- Background: PubMed 25340221National Clinical Guideline Centre (UK). The Epilepsies: The Diagnosis and Management of the Epilepsies in Adults and Children in Primary and Secondary Care: Pharmacological Update of Clinical Guideline 20. London: Royal College of Physicians (UK); 2012 Jan. Available from http://www.ncbi.nlm.nih.gov/books/NBK247130/
- Backgroundhttp://www.charliefoundation.org/offering-hope.html Accessed November 14, 2013
- Background: PubMed 21514240Lee PR, Kossoff EH. Dietary treatments for epilepsy: management guidelines for the general practitioner. Epilepsy Behav. 2011 Jun;21(2):115-21. doi: 10.1016/j.yebeh.2011.03.008. Epub 2011 Apr 21.
- Background: PubMed 22575229Williams E, Abrahams J, Maguire A, Harris G. A parent's perspective on dietary treatments for epilepsy. Epilepsy Res. 2012 Jul;100(3):338-43. doi: 10.1016/j.eplepsyres.2011.09.024. Epub 2012 May 8.
- Background: PubMed 21856128Kossoff EH, Caraballo RH, du Toit T, Kim HD, MacKay MT, Nathan JK, Philip SG. Dietary therapies: a worldwide phenomenon. Epilepsy Res. 2012 Jul;100(3):205-9. doi: 10.1016/j.eplepsyres.2011.05.024.
- Background: PubMed 10573471Gilbert DL, Pyzik PL, Vining EP, Freeman JM. Medication cost reduction in children on the ketogenic diet: data from a prospective study. J Child Neurol. 1999 Jul;14(7):469-71. doi: 10.1177/088307389901400712.
- Background: PubMed 11902372Mandel A, Ballew M, Pina-Garza JE, Stalmasek V, Clemens LH. Medical costs are reduced when children with intractable epilepsy are successfully treated with the ketogenic diet. J Am Diet Assoc. 2002 Mar;102(3):396-8. doi: 10.1016/s0002-8223(02)90091-x.
- Background: PubMed 9823827Vining EP, Freeman JM, Ballaban-Gil K, Camfield CS, Camfield PR, Holmes GL, Shinnar S, Shuman R, Trevathan E, Wheless JW. A multicenter study of the efficacy of the ketogenic diet. Arch Neurol. 1998 Nov;55(11):1433-7. doi: 10.1001/archneur.55.11.1433.
- Background: PubMed 9832569Freeman JM, Vining EP, Pillas DJ, Pyzik PL, Casey JC, Kelly LM. The efficacy of the ketogenic diet-1998: a prospective evaluation of intervention in 150 children. Pediatrics. 1998 Dec;102(6):1358-63. doi: 10.1542/peds.102.6.1358.
- Background: PubMed 18456557Neal EG, Chaffe H, Schwartz RH, Lawson MS, Edwards N, Fitzsimmons G, Whitney A, Cross JH. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol. 2008 Jun;7(6):500-6. doi: 10.1016/S1474-4422(08)70092-9. Epub 2008 May 2.
- Individual participant dataSharing planned: No
Related trials for Epilepsy
Enrolling by invitation
An Examination of Cognitive and Sensorimotor Processes in Patients With Epilepsy
Epilepsy
RecruitingObservational study
Surgery as a Treatment for Medically Intractable Epilepsy
Epilepsy, Epilepsy, Temporal Lobe
RecruitingObservational study
Tumor Related Epilepsy
Epilepsy, Cancer
RecruitingObservational study
Investigating Epilepsy: Screening and Evaluation
Seizures, Epilepsy
Recruiting
Optimizing Brain Stimulation Parameters
Epilepsy; Seizure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ryan W Lee, MD principal investigator
Shriners Hospitals for Children, Honolulu
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Ketogenic Diet in people with Epilepsy, run by Shriners Hospitals for Children at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Sep 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from baseline in the core symptoms of epilepsy (seizure frequency/severity) (time frame: Pre- and post-ketogenic diet intervention (at baseline, and after three and six months on the ketogenic diet)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02497105, which also lists 19 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Sep 2019.